WallStSmart

AstraZeneca PLC (AZN)vsInteger Holdings Corp (ITGR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 3157% more annual revenue ($60.44B vs $1.86B). AZN leads profitability with a 17.2% profit margin vs 7.6%. ITGR appears more attractively valued with a PEG of 1.37. ITGR earns a higher WallStSmart Score of 62/100 (C+).

AZN

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 8.5Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

ITGR

Buy

62

out of 100

Grade: C+

Growth: 7.3Profit: 5.5Value: 7.3Quality: 6.5
Piotroski: 3/9Altman Z: 1.97
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+6.6%)

Margin of Safety

+6.6%

Fair Value

$220.34

Current Price

$182.85

$37.49 discount

UndervaluedFair: $220.34Overvalued
ITGRUndervalued (+33.0%)

Margin of Safety

+33.0%

Fair Value

$130.14

Current Price

$88.12

$42.02 discount

UndervaluedFair: $130.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$286.68B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
23.5%9/10

Every $100 of equity generates 24 in profit

Operating MarginProfitability
28.2%8/10

Strong operational efficiency at 28.2%

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

ITGR2 strengths · Avg: 9.0/10
EPS GrowthGrowth
52.9%10/10

Earnings expanding 52.9% YoY

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Areas to Watch

AZN3 concerns · Avg: 3.3/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

ITGR4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.5%4/10

0.5% revenue growth

Altman Z-ScoreHealth
1.974/10

Grey zone — moderate risk

Profit MarginProfitability
7.6%3/10

7.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.

Bull Case : ITGR

The strongest argument for ITGR centers on EPS Growth, Price/Book. PEG of 1.37 suggests the stock is reasonably priced for its growth.

Bear Case : AZN

The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.

Bear Case : ITGR

The primary concerns for ITGR are Revenue Growth, Altman Z-Score, Profit Margin.

Key Dynamics to Monitor

AZN profiles as a mature stock while ITGR is a value play — different risk/reward profiles.

ITGR carries more volatility with a beta of 0.66 — expect wider price swings.

AZN is growing revenue faster at 12.5% — sustainability is the question.

AZN generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (62/100 vs 62/100), backed by strong 17.2% margins and 12.5% revenue growth. ITGR offers better value entry with a 33.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Integer Holdings Corp

HEALTHCARE · MEDICAL DEVICES · USA

Integer Holdings Corporation is an outsourced manufacturer of medical devices in the United States, Puerto Rico, Costa Rica, and internationally. The company is headquartered in Plano, Texas.

Want to dig deeper into these stocks?